Right patient, right dose, right time

Right patient, right dose, right time

A new study uses AI to modify drug doses for personalized cancer treatment.

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

GENA, by SIVOTEC, Partners with University of Miami to Advance a Private Language Model for Healthcare Innovation

Collaboration will focus on developing a purpose-built AI platform designed to power the next era of genomic and precision medicine. MIAMI, FL, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- SIVOTEC Inc., the company behind the GENA platform (GENADNA.AI), is proud to announce a strategic partnership with the University of Miami’s Frost Institute for Data Science and Computing (IDSC) to accelerate the development of its GENA Private Language…

Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care

This initiative aims to harness biological and clinical insights, identify new drug targets, and create therapeutics for the oncology sector. The collaboration will leverage de-identified oncology data of The post Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care appeared first on Pharmaceutical Business review.

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos - Pharmaceutical Technology

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.